3P Biopharmaceuticals initiates partnership with American Biotech Zhittya for Parkinson’s disease treatment

[Pamplona, 21 October, 2019] 3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, and the American biotech company, Zhittya Genesis Medici

3P and Zhittya began their relationship at the beginning of 2019 with 3P being selected as the CDMO to transfer the process for scaling up and performing cGMP manufacturing for clinical studies. After successfully achieving transfer of the process, 3P anticipates manufacturing of the first cGMP batch by the second quarter of 2020. More>>

Merck Launches ADC ExpressTM Services to Accelerate Pre-clinical Conjugation Candidate Selection

• Provides rapid production of antibody drug conjugates (ADCs) for best candidate selection • Established platform technology to reliably scale target molecules • Reduces time to clinic through comprehensive ADC services from pre-clinical to commercial from a single source More>>

Discussing developments on Highly Potent APIs with industry expert, Richard Arnett for the HPAPI USA conference 2019

SMI Reports: Exclusive interview with industry expert, Richard Arnett Manager, Industrial Hygiene, Pharmascience for the HPAPI USA conference 2019

Ahead of the 2019 HPAPI USA Conference taking place in Boston on 21st – 22nd October, SMi caught up with Richard Arnett, Manager, Industrial Hygiene, Pharmascience who is speaking on Day Two of the agenda. Richard shared his thoughts on how the industry has developed and briefly touched on what he will be discussing in October. More>>

A new market reference added to Safe’n’Sound®, our passive safety device platform

Safe’n’Sound® is on the market in Europe with a newly registered injectable medication. The commercial launch of HULIO™ (Adalimumab Biosimilar) was initiated in selected European markets on October 19,2018. Hulio™, developed by Fujifilm Kyowa Kirin Biologics Co., Ltd. and marketed in the European Union by Mylan N.V. is approved as a biosimilar for the same indications as the reference product, Humira®. More>>

Huge boom in Korean Pharma reported at CPhI Korea

Event sees new Memorandum of Understanding signed by PROLMED and KPTA

Amsterdam, 19th September 2019: The recently-closed CPhI Korea – co-organised by Informa Markets and the Korea Pharmaceutical Traders Association (KPTA) – has seen a surge in growth across domestic and international pharma companies, as well as a sizable rise in overall attendees. As reported earlier this year in the provisional findings of the CPhI Pharma Index[1], Korea has seen a rapid growth in its international reputation (seeing its ‘overall competitiveness’ rise 14% in the last two years), which is now translating into a sizable growth in the market and at the event. More>>

3P Biopharmaceuticals receives FDA approval

The FDA classified 3P facilities as acceptable for the manufacture of the target molecule, and appropriate for its commercialization in the US market, once the product is authorized

[Pamplona, September 16th, 2019] 3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organisation (CDMO) specialized in process development and GMP manufacturing of biologics, receives FDA approval after completing the Pre-Approval Inspection (PAI) conducted at the 3P drug substance manufacturing facility. More>>

IATA CEIV Pharma certificate of Turkish Cargo renewed

Turkish Cargo, the air cargo brand flying to the most countries around the world, extended the validity period of its IATA CEIV (Center of Excellence for Independent Validators) Pharma certificate to 2022, proving its success in all processes throughout the air transportation of medicinal products. More>>

Phillips-Medisize Enters Agreement with Global Pharmaceutical Company to Acquire Exclusive Ownership of Patents for an Innovative Mini-tablet Dispenser

HUDSON, WI – September 10, 2019 – Phillips-Medisize, a Molex company, announced today an agreement with a Global Pharmaceutical Company, where Phillips-Medisize acquired exclusive ownership of patents supporting an innovative mini-tablet dispenser to accommodate the varied and customized oral dispensing needs of patients. More>>

Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market explored ahead of CPhI MEA

Saudi Arabia’s pharmaceutical market expected to grow at a CAGR of 5.5% until 2023. Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth More>>

The CPhI Annual Report

Take part in pharma’s largest reputation survey

The global pharmaceutical landscape is evolving at an extraordinary pace as manufacturing capabilities, drug development technologies, and regulation advances creating new ways of innovating drugs and better serving patients. More>>